Prevention and Treatment of Acute Kidney Injury Associated with High-Dose Methotrexate
Kidney360 · 2025-03 · 6 (3) · 476-481
DOI: 10.34067/kid.0000000725 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney360, online erschienen am 31.01.2025. Verfasst von Stanislas Faguer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Organ Transplantation, French Intensive Care Renal Network (F.I.R.N), University Hospital of Toulouse, Toulouse, France. Hauptthemen laut MEDLINE: Methotrexate, Acute Kidney Injury, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
AKI is a rare but life-threatening complication of the administration of methotrexate (MTX) at high doses (≥1 g/m 2 ) for the treatment of solid or hematological malignancies. MTX overexposure can lead to MTX-AKI and subsequent higher risk of extrakidney toxicities, morbidity, and mortality. MTX-AKI can also lead to secondary CKD requiring a reduced dose or contraindication for subsequent MTX infusions, thus worsening the cancer-related prognosis. Treatment of MTX-AKI is mainly preventive, combining alkaline hyperhydration, withdrawal of all nephrotoxic agents and drugs that modulate the metabolism of MTX, metabolic salvage using leucovorin (folinic acid), and close monitoring of serum MTX and creatinine concentrations. Glucarpidase (carboxypeptidase-G2), a recombinant bacterial enzyme that hydrolyzes MTX into two noncytotoxic metabolites, should be considered for patients with MTX overexposure to prevent and lessen AKI and other potential toxicities. This article provides a comprehensive review of MTX metabolism, mechanisms and prevention of MTX-AKI, and its management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nephrology and Organ Transplantation, French Intensive Care Renal Network (F.I.R.N), University Hospital of Toulouse, Toulouse, France.
- Faculty of Health, University of Toulouse-3, Toulouse, France.
- Renal Fibrosis Lab, INSERM UMR1297, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France.
- Department of Hematology, Oncopole - Cancer Institute of Toulouse, University Hospital of Toulouse, Toulouse, France.
ORCID-Profile: Stanislas Faguer
Zitieren
APA
Faguer, S., Medrano, C., Tavitian, S., & Oberic, L. (2025). Prevention and Treatment of Acute Kidney Injury Associated with High-Dose Methotrexate. Kidney360, 6(3), 476-481. https://doi.org/10.34067/kid.0000000725
Vancouver
Faguer S, Medrano C, Tavitian S, Oberic L. Prevention and Treatment of Acute Kidney Injury Associated with High-Dose Methotrexate. Kidney360. 2025;6(3):476-481. doi:10.34067/kid.0000000725
BibTeX
@article{Faguer2025,
author = {Faguer, Stanislas and Medrano, Chloé and Tavitian, Suzanne and Oberic, Lucie},
title = {Prevention and Treatment of Acute Kidney Injury Associated with High-Dose Methotrexate},
journal = {Kidney360},
year = {2025},
volume = {6},
number = {3},
pages = {476--481},
doi = {10.34067/kid.0000000725}
}
EUVIMED